Journal Mobile Options
Table of Contents
Vol. 21, No. 3, 2003
Issue release date: 2003
Dig Dis 2003;21:198–213
(DOI:10.1159/000073337)

What We Have Learned about Cachexia in Gastrointestinal Cancer

Palesty J.A. · Dudrick S.J.
St. Mary’s Hospital, Yale University Affiliate, Department of Surgery, Waterbury, Conn., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

It is appreciated widely by clinicians that significant malnutrition accompanies malignant processes in approximately 50% of patients and eventually leads to severe wasting which accounts for approximately 30% of cancer-related deaths overall, 30–50% of deaths in patients with gastrointestinal tract cancers, and up to 80% of deaths in patients with advanced pancreatic cancer. The body wasting known as cancer cachexia is a complex syndrome characterized by progressive tissue depletion and decreased nutrient intake that is manifested clinically as inexplicable, recalcitrant anorexia and inexorable host weight loss. Decreased nutritional intake, increased metabolic expenditure and dysfunctional metabolic processes, including hormonal and cytokine-related abnormalities, all appear to play roles in the development of cancer cachexia. Although this condition of advanced protein-calorie malnutrition, sometimes described as the cancer anorexia-cachexia syndrome, is not entirely understood, it appears to be multifactorial, is a major cause of morbidity and mortality in cancer patients, and ultimately leads to death. Therapeutic interventions have met with little success, and, regardless of tremendous efforts throughout the decades, the exact nature of the mediators responsible for cancer cachexia remain elusive. The pathogenesis of cancer cachexia appears to be related to proinflammatory cytokines, alterations in the neuroendocrine axis and tumor-derived catabolic factors. Despite trials of conventional and/or aggressive nutritional support by a myriad of feeding techniques, patients with cancer cachexia have failed to gain consistent significant benefits in terms of weight gain, functional ability, quality of life or survival. Additionally, attempts to ameliorate the abnormal clinical and metabolic features of cancer cachexia with a variety of pharmacologic agents have met with only limited success. Either until cancer of the gastrointestinal tract can be cured or until it is possible to identify the exact causes and mechanisms of the cancer cachexia syndrome, the most realistic and practical options currently are directed toward minimizing adverse gastrointestinal side effects or complications of the malignant process and/or therapy, as well as increasing appetite, food intake and nutrient utilization in an effort to enhance quality of life and improve survival.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Toomey D, Redmond P, Bouchier-Hayes D: Mechanisms mediating cancer cachexia. Cancer 1995;76:2418–2426.
  2. Inui A: Cancer anorexia-cachexia syndrome. CA Cancer J Clin 2002;52:72–91.
  3. Puccio M, Nathanson: The cancer cachexia syndrome. Semin Oncol 1997;24:277–287.
  4. DeWys W: Pathophysiology of cancer cachexia: Current understanding and areas of future research. Cancer Res 1982;42(suppl):721–726.
  5. Warren S: The immediate causes of death and cancer. Am J Med Sci 1932;184:610–615.
  6. Harrison LE, Fong Y: Enteral nutrition in the cancer patient; in Rombeau JL, Rolandelli RH (eds): Clinical Nutrition Enteral and Tube Feeding, ed 3. Philadelphia, Saunders, 1997, pp 300–323.
  7. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491–497.
  8. Bozzetti F, Migliavacca S, Scotti A, Bonalumi MG, Scarpa D, Baticci F, Ammatuna M, Pupa A, Terno G, Sequeira C, Masserini C, Emanuelli H: Impact of cancer, type, site, stage and treatment on the nutritional status of patients. Ann Surg 1982;196:170–179.
  9. Meguid MM, Meguid V: Preoperative identification of the surgical cancer patient in need of postoperative supportive total parenteral nutrition. Cancer 1985;55(suppl):258–262.
  10. Kotler DP: Cachexia. Ann Intern Med 2000;133:622–634.
  11. Rosenbaum K, Wang J, Peirson RN Jr et al: Time-dependent variation in weight and body composition in healthy adults. J Parenter Enteral Nutr 2000;24:52–55.
  12. Brennan M: Uncomplicated starvation versus cancer cachexia. Cancer Res 1977;37:2359–2364.
  13. Shamberger RJ: Nutrition and Cancer. New York, Plenum Press, 1984, pp 353–366.
  14. Shils ME: Nutrition and Diet in Cancer Management; in Shils ME, Olson JA, Shike M (eds): Modern Nutrition in Health and Disease, ed 8. Philadelphia, Lea & Febiger, 1994, pp 1317–1348.
  15. Heber D, Tchekmedyian NS: Mechanisms of cancer cachexia. Contemp Oncol 1995, special issue, pp 6–10.
  16. Langstein HN, Norton JA: Mechanisms of cancer cachexia. Hematol Oncol Clin North Am 1991;5:103–123.
  17. Staal-van den Brekel AJ, Schols AM, ten Velde GP, Buurman WA, Wouters EF: Analysis of the energy balance in lung cancer patients. Cancer Res 1994;54:6430–6433.
  18. Wigmore SJ, Plester CE, Ross JA, Fearon KC: Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 1997;84:196–197.
  19. Bruera E: ABC of palliative care. Anorexia, cachexia and nutrition. BMJ 1997;315:1219–1222.
  20. Barber MD, Ross JA, Fearon KC: Cancer cachexia. Surg Oncol 1999;8:133–141.
  21. Padilla GV: Psychological aspects of nutrition and cancer. Surg Clin North Am 1986;66:1121–1135.
  22. Cangiano C, Laviano A, Meguid MM, Mulieri M, Conversano L, Preziosa I, Rossi-Fanelli F: Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst 1996;88:550–552.
  23. Flier JS: Clinical review 94: What’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metab 1998;83:1407–1413.
  24. Schwartz MW, Dallman MF, Woods SC: Hypothalamic response to starvation: Implications for the study of wasting disorders. Am J Physiol 1995;269:949–957.
  25. Schwartz MW, Seeley RJ: Seminars in medicine of the Beth Israel Deaconess Medical Center. Neuroendocrine responses to starvation and weight loss. N Engl J Med 1997;336:1802–1811.
  26. Inui A: Feeding and body-weight regulation by hypothalamic neuropeptides – Mediation of the actions of leptin. Trends Neurosci 1999;22:62–67.

    External Resources

  27. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 1998;395:763–770.
  28. Elmquist JK, Maratos-Flier E, Saper CB, Flier JS: Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1998;1:445–450.
  29. Woods SC, Seeley RJ, Porte D Jr, Schwartz MW: Signals that regulate food intake and energy homeostasis. Science 1998;280:1378–1383.
  30. Bray GA, York DA: The Mona Lisa hypothesis in the time of leptin. Recent Prog Horm Res 1998;53:95–117.
  31. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS: Interacting appetite-regulating pathways in the hypothalamic regulations of body weight. Endocr Rev 1999;20:68–100.
  32. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature 2000;404:661–671.
  33. Inui A: Transgenic approach to the study of body weight regulation. Pharmacol Rev 2000;52:35–61.
  34. Inui A: Transgenic study of energy homeostasis equation: Implications and confounding influences. FASEB J 2000;14:2158–2170.
  35. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL: A receptor sub-type involved a neuropeptide-Y induced food intake. Nature 1996;382:168–171.
  36. Donaldson CJ, Sutton SW, Perrin, Corrigan AZ, Lewis KA, Rivier JE, Vaughan JM, Vale WW: Cloning and characterization of human urocortin. Endocrinology 1996;137:2167–2170.
  37. Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W, Koob GF: Appetite suppressing effect of urocortin, a CRF-related neuropeptide. Science 1996;273:1561–1564.
  38. Tisdale MJ: Biology of cachexia. J Natl Cancer Inst 1997;89:1763–1773.
  39. Inui A: Cancer anorexia-cachexia syndrome: Are neuropeptides the key? Cancer Res 1999;59:4493–4501.
  40. Moldawer LL, Rogy MA, Lowry SF: The role of cytokines in cancer cachexia. J Parenter Enteral Nutr 1992;16(suppl):43–49.
  41. Noguchi Y, Yoshikawa T, Matsumoto A, Svaniger G, Gelin J: Are cytokines possible mediators of cancer cachexia? Surg Today 1996;26:467–475.
  42. Matthys P, Billiau A: Cytokines and cachexia. Nutrition 1997;13:763–770.
  43. Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R, Lundholm K: Role of endogenous tumor necrosis factor-α and interleukin-1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991;51:415–421.
  44. Moldawer LL, Copeland EM: Proinflammatory cytokines, nutritional support and the cachexia syndrome: Interactions and therapeutic options. Cancer 1997;79:1828–1839.
  45. Haslett PA: Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998;25(suppl):53–57.
  46. Mantovani G, Maccio A, Lai P, Massa E, Ghiani M, Santona MC: Cytokine involvement in cancer-related anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone. Semin Oncol 1998;25(suppl 6):45–52.
  47. Marks DL, Ling N, Cone RD: Role of the central melanocortin system in cachexia. Cancer Res 2001;61:1432–1438.
  48. Wisse BE, Frayo RS, Schwartz MW, Cummings DE: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001;142:3292–3301.
  49. Lechan RM, Tatro JB: Hypothalamic melanocortin signaling in cachexia. Endocrinology 2001;142:3288–3291.
  50. Bartlett DL, Charland SL, Torosian MH: Reversal of tumor associated hyperglucagonemia as treatment for cancer cachexia. Surgery 1995;118:87–91.
  51. Beck SA, Mulligan HD, Tisdale MJ: Lipolytic factors associated with murine and human cancer cachexia. J Natl Cancer Inst 1990;82:1922–1926.
  52. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M: Characterization of a cancer cachectic factor. Nature 1996;379:739–742.
  53. Beck SA, Smith KL, Tisdale MJ: Anti-cachectic and anti-tumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 1991;51:6089–6093.
  54. Nelson KA, Walsh D, Sheehan FA: The cancer anorexia-cachexia syndrome. J Clin Oncol 1994;12:213–225.
  55. Nitenberg G, Raynard B: Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 2000;34:137–168.
  56. DeWys WD: Anorexia as a general effect of cancer. Cancer 1979;43(suppl):2013–2019.
  57. DeWys WD, Walters K: Abnormalities of taste sensation in cancer patients. Cancer 1975;36:1888–1896.
  58. Bernstein IL: Learned taste aversions in children receiving chemotherapy. Science 1978;200:1302–1303.
  59. Glass MJ, Billington CJ, Levine AS: Opioids and food intake: Disturbed functional neural pathways? Neuropeptides 1999;33:360–368.
  60. Fujimiya M, Inui A: Peptidergic regulation of gastrointestinal motility in rodents. Peptides 2000;21:11565–1582.
  61. Tache Y, Garrick T, Raybould H: Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology 1990;98:517–528.
  62. Inui A, Okano H, Miyamoto M, Aoyama N, Uemoto M, Baba S, Kasuga MI: Delayed gastric emptying in bulimic patients. Lancet 1995;346:1240.
  63. Okano H, Inui A, Ueno N, Morimoto S, Ohmoto A, Miyamoto M, Aoyama N, Nakajima Y, Baba S, Kasuga M: EM523l, a nonpeptide motilin agonist, stimulated gastric emptying and pancreatic polypeptide secretion. Peptides 1996;17:895–900.
  64. Mitchell EP: Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 1992;19:566–579.
  65. Copeland EM, MacFadyen BV Jr, Lanzotti VJ, Dudrick SJ: Intravenous hyperalimentation as an adjunct to cancer chemotherapy. Am J Surg 1975;129:167–173.
  66. Copeland EM, Souchon EA, MacFadyen BV Jr, Rapp MA, Dudrick SJ: Intravenous hyperalimentation as an adjunct to radiation therapy. Cancer 1977;39:609–616.
  67. Dudrick SJ, MacFadyen BV Jr, Souchon EA, Englert DM, Copeland EM: Parenteral nutrition techniques in cancer patients. Cancer Res 1977;37:2440–2450
  68. Klein SM, Simes J, Blackburn GL: Total parenteral nutrition and cancer clinical trials. Cancer 1986;58:1378–1386.
  69. Lowry SF, Brennan MF: Intravenous feeding of the cancer patient; in Rombeau JL, Caldwell MD (eds): Parenteral Nutrition. Philadelphia, Saunders, 1986.
  70. Shike M, Brennan MF: Supportive care of the cancer patient; in DeVita VT, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology, ed 3. Philadelphia, Lippincott, 1989.
  71. Lipman TO: Clinical trials of nutritional support in cancer. Parenteral and enteral therapy. Hematol Oncol Clin North Am 1991;5:91–102.
  72. Sikora SS, Ribeiro U, Kane JM 3rd, Landreneau RJ, Lembersky B, Posner MC: Role of nutrition support during induction chemoradiation therapy in esophageal cancer. J Parenter Enteral Nutr 1998;22:18–21.
  73. Body JJ: Metabolic sequelae of cancers (excluding bone marrow transplantation). Curr Opin Clin Nutr Metab Care 1999;2:339–344.
  74. Body JJ: The syndrome of anorexia-cachexia. Curr Opin Oncol 1999;11:255–260.
  75. Bozetti F: Effects of artificial nutrition on the nutritional status of cancer patients. J Parenter Enteral Nutr 1989;13:406–420.
  76. Chen MK, Souba WW, Copeland EM: Nutritional support of the surgical oncology patient. Hematol Oncol Clin North Am 1991;5:125–145.
  77. Miller M: Can reducing caloric intake also help reduce cancer? J Natl Cancer Inst 1998;90:1766–1767.
  78. Nelson KA: The cancer anorexia-cachexia syndrome. Semin Oncol 2000;27:64–68.
  79. Mercadante S: Parenteral versus enteral nutrition in cancer patients: Indications and practice. Support Care Cancer 1998;6:85–93.
  80. Gagnon B, Bruera E: A review of the drug treatment of cachexia associated with cancer. Drugs 1998;55:675–688.
  81. Loprinzi CL, Michalak JC, Schaid DJ: Phase three evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762–767.
  82. Mantovani G, Maccio A, Massa E, Madeddu C: Managing cancer-related anorexia/cachexia. Drugs 2001;61:499–514.

    External Resources

  83. Downer S, Joel S, Allbright A, Plant H, Stubbs L, Talbot D, Slevin M: A double-blind placebo-controlled trial of medroxyprogesterone acetate in cancer cachexia. Br J Cancer 1993;67:1102–1105.
  84. Simons JP, Aaronson NK, Vansteenkiste JF, ten Velde GP, Muller MJ, Drenth BM, Erdkamp FL, Cobben EG, Schoon EJ, Smeets JB, Schouten HC, Demedts M, Hillen HF, Blijham GH, Wouters EF: Effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced stage non-hormone sensitive cancer: A placebo-controlled multicenter study. J Clin Oncol 1996;14:1077–1084.
  85. Fietkau R, Riepl M, Kettner H: Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Eur J Cancer 1997;33:75–79.
  86. Loprinzi CL, Kugler J, Sloan J: Phase III randomized comparison of megestrol acetate, dexamethasone and fluoxymesterone for the treatment of cancer anorexia/cachexia. Proc ASCO 1997;16:48A.
  87. McCarthy WD, Crowder RE, Dryden S, Williams G: Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994;265:99–102.
  88. Costa AM, Spence KT, Plata-Salaman CR, French-Mullen JM: Residual Ca2+ channel current modulation by megestrol acetate via a G-protein-a s-subunit in rat hypothalamic neurones. J Physiol 1995;487:291–303.
  89. Mantovani G, Maccio A, Esu S, Lai P, Santona MC, Massa E, Dessi D, Melis G, Del Giacco S: Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patient. Biochem Soc Trans 1997;25:296S.
  90. DeVita VT Jr, Hellman S, Rosenberg SA: Cancer Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott Raven, 1997.
  91. Bruera E, Fainsinger RL: Clinical management of cachexia and anorexia; in Doyle D, Hanks G, MacDonald N (eds): Oxford Textbook of Palliative Medicine. London, Oxford Medical, 1993, pp 330–337.
  92. Steer KA, Kurtz AB, Honour JW: Megestrol-induced Cushing’s syndrome. Clin Endocrinol 1995;42:91–93.
  93. Leinung MC, Liporace R, Miller CH: Introduction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995;122:843–845.
  94. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990;66:1279–1282.
  95. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, Mailliard JA, Johnson PS, Ebbert LP, Geeraerts LH: Controlled trial of megestrol acetate for the treatment of cancer, anorexia and cachexia. J Natl Cancer Inst 1990;82:1127–1132.
  96. Heckmayr M, Gatzeneir U: Treatment of cancer weight loss in patients with advanced lung cancer. Oncology 1992;49(suppl 2):32–34.
  97. Feliu J, Gonzalez-Baron M, Berracal A: Usefulness of megestrol acetate in cancer cachexia and anorexia. J Clin Oncol 1992;15:436–440.
  98. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607–1609.
  99. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R: Action of oral methylprednisolone in terminal cancer patients: A randomized, double-blind study. Cancer Treat Rep 1985;69:751–754.
  100. Popiela T, Lucchi R, Giongo F: Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 1989;25:1823–1829.
  101. Willox JC, Corr J, Shaw J, Richardson M, Calman KC, Drennan M: Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 1984;288:27.
  102. Gagnon B, Bruera E: A review of the drug treatment of cachexia associated with cancer. Drugs 1998;55:675–688.
  103. Fainsinger R: Pharmacological approach to cancer anorexia and cachexia; in Bruera E, Higginson I (eds): Cachexia-Anorexia in Cancer Patients. Oxford, Oxford University Press, 1996, pp 128–140.
  104. Argiles JM, Meijsing SH, Pallares-Trujillo J, Guirao X, Lopez-Soriano FJ: Cancer cachexia: A therapeutic approach. Med Res Rev 2001;21:83–101.
  105. Daly JM, Redmond HP, Gallagher H: Perioperative nutrition in cancer patients. J Parenter Enteral Nutr 1992;16(suppl):100–105.
  106. Forbes GB: The effect if anabolic steroids on lean body mass: The dose-response curve. Metabolism 1985;34:571–573.
  107. Chlebowski RT, Herrold J, Ali I, Oktay E, Chlebowski JS, Ponce AT, Heber D, Block JB: Influence of nadrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986;58:183–186.
  108. Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, Dose AM, Athmann LM, Mailliard JA, McCormack GW, Gerstner JB, Schray MF: A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657–2662.
  109. Meguid MM, Fetissov SO, Varma M, Sato T, Zhang L, Laviano A, Rossi-Fanelli F: Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000;16:843–857.

    External Resources

  110. Laviano A, Meguid MM, Yang ZJ, Gleason JR, Cangiano C, Fanelli FR: Cracking the riddle of cancer anorexia. Nutrition 1996;12:706–710.
  111. Moertel CG, Kvols LK, Rubin J: A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991;67:33–36.
  112. Edelman MJ, Gandara DR, Meyers FJ, Ishii R, O’Mahony M, Uhrich M, Lauder I, Houston J, Gietzen DW: Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer 1999;86:684–688.
  113. Tayek JA, Bistrian BR, Hehir DJ, Martin R, Moldawer LL, Blackburn GL: Improved protein kinetics and albumin syntheses by branched chained amino acid-enriched total parenteral nutrition in cancer cachexia. A prospective randomized crossover trial. Cancer 1986;58:147–157.
  114. Cangiano C, Laviano A, Meguid MM, Mulieri M, Conversano L, Preziosa I, Rossi-Fanelli F: Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst 1996;88:550–552.
  115. Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC, Fearon KC: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996;12(suppl):27–30.
  116. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC: The effect of an oral nutritional supplement enriched with fish oil on weight loss in patients with pancreatic cancer. Br J Cancer 1999;81:80–86.
  117. Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F: Dietary ω3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: A randomized control trial. Cancer 1998;82:395–402.
  118. Periera J, Bruera E: Chronic nausea; in Bruera E, Higginson I (eds): Cachexia-Anorexia in Cancer Patients. Oxford, Oxford University Press, 1996, pp 23–27.
  119. Davis MP, Dickerson D: Cachexia and anorexia: Cancer’s covert killer. Support Care Cancer 2000;8:180–187.
  120. Loprinzi CL, Kuross SA, O’Fallon JR, Gesme DH Jr, Gerstner JB, Rospond RM, Cobau CD, Goldberg RM: Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994;12:1121–1125.
  121. Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, Kugler JW, Jett JR, Ghosh C, Pfeifle DM: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnoses non-small-cell lung cancer. J Clin Oncol 1994;12:1126–1129.
  122. Kosty MP, Fleishman SB, Herndon JE 2nd, Coughlin K, Kornblith AB, Scalzo A, Morris JC, Mortimer J, Green MR: Cisplatin, vinblastine and hydrazine sulfate in advanced, non-small-cell lung cancer: A randomized, placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994;12:1113–1120.
  123. Bruera E, Neumann CM, Pituskin E, Calder K, Ball G, Hanson J: Thalidomide in patients with cachexia due to terminal cancer: Preliminary report. Ann Oncol 1999;10:857–859.
  124. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, Ruiz-Palacios GM: Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial. AIDS 1996;10:1501–1507.
  125. Haslett P, Tramontana J, Burroughs M, Hempstead M, Kaplan G: Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 1997;24:1223–1227.
  126. McMillan DC, O’Gorman P, Fearon KC, McArdle CS: A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 1997;76:788–790.
  127. Dezube BJ, Sherman ML, Fridovich-Keil JL, Allen-Ryan J, Pardee AB: Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: A pilot study. Cancer Immunol Immunother 1993;36:57–60.
  128. Lissoni P, Ardizzoia A, Barni S, Pittalis S, Rossini F, Porta A, Tancini G: Characterization of cancer-related disseminated intravascular coagulation in relation to tumor necrosis factor-α blood concentrations: Possible therapeutic role of pentoxifylline. Tumori 1996;82:78–80.
  129. Goldberg RM, Loprinzi CL, Mailliard JA, O’Fallon JR, Krook JE, Ghosh C, Hestorff RD, Chong SF, Reuter NF, Shanahan TG: Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995;13:2856–2859.
  130. Tanaka Y, Eda H, Fujimoto K, Tanaka T, Ishikawa T, Ishitsuka H: Anticachectic activity of 5-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 1990;50:4528–4532.
  131. Hussey HJ, Todorov PT, Field WN, Inagaki N, Tanaka Y, Ishitsuka H, Tisdale MJ: Effect of a fluorinated pyrimidine on cachexia and tumor growth in murine cachexia models: Relationship with a proteolysis inducing factor. Br J Cancer 2000;83:56–62.
  132. Nelson K, Walsh D, Deeter P, Sheehan F: A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994;10:14–18.
  133. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG: Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991;40:695–700.
  134. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89–97.
  135. Fainsinger RL, Tapper M, Bruera E: A perspective on the management of delirium in the terminally ill. J Palliat Care 1993;9:4–8.
  136. Costelli P, Garcia-Martinez C, Llovera M, Carbo N, Lopez-Soriano FJ, Agell N, Tessitore L, Baccino FM, Argiles JM: Muscle protein waste in tumor-bearing rats is effectively antagonized by a β2-adrenergic agonist (clenbuterol): Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 1995;95:2367–2372.
  137. Chance WT, Cao LQ, Zhang FS, Foley-Nelson T, Fischer JE: Clenbuterol treatment increases muscle mass and protein content of tumor-bearing rats maintained on total parenteral nutrition. J Parenter Enteral Nutr 1991;15:530–535.
  138. Rehfeldt C, Weikard R, Reichel K: The effect of the ß-adrenergic agonist clenbuterol on the growth of skeletal muscles of rats. Arch Tierernähr 1994;45:333–344.
  139. Young OA, Watkins S, Oldham JM: The role of insulin-like growth factor I in clenbuterol-stimulated growth in growing lambs. J Anim Sci 1995;73:3069–3077.
  140. Zhou GH, Han ZK: Effects of dietary supplementation of β2-adrenergic agonist clenbuterol on carcass characteristics and some metabolites in ducks. Br Poult Sci 1994;35:355–361.
  141. Carbo N, Lopez-Soriano J, Tarrago T, Gonzalez O, Llovera M, Lopez-Soriano FJ, Argiles JM: Comparative effects of β2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett 1997;115:113–118.
  142. Maltin CA, Delday MI, Watson JS, Heys SD, Nevison IM, Ritchie IK, Gibson PH: Clenbuterol, a ß-adrenoreceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci 1993;84:651–654.

    External Resources

  143. McMillan DC, Leen E, Smith J, Sturgeon C, Preston T, Cooke TG, McArdle CS: Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 1995;21:531–534.
  144. Preston T, Fearon KC, McMillan DC, Winstanley FP, Slater C, Shenkin A, Carter DC: Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br J Surg 1995;82:229–234.
  145. Wigmore SJ, Falconer JS, Plester CE, Ross JA, Maingay JP, Carter DC, Fearon KC: Ibuprofen reduces energy expenditure and acute-phase protein production in cancer patients compared with placebo in pancreatic cancer patients. Br J Cancer 1995;72:185–188.
  146. McMillan DC, Wigmore SJ, Fearon KC, O’Gorman P, Wright CE, McArdle CS: A prospective randomized study of megesterol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999;79:495–500.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50